Edesa Biotech, Inc. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 62/100
What the filing says
Edesa reported Q3 2026 net loss of $5.4M ($0.60/share) vs. $1.7M prior year; 9-month loss $11.9M ($1.40/share) vs. $5.0M prior year. Operating expenses surged to $5.5M (Q3) and $12.2M (9-month YTD) due to Phase 2 EB06 manufacturing and trial prep in vitiligo. Cash position $10.3M at June 30, 2026, down from $10.8M Sept 2025. Company activated first investigational sites post-quarter and expects Canadian patient recruitment in coming weeks; paridiprubart respiratory program showed exploratory mortality benefit in ARDS+AKI patients.
Why this rating
Accelerating burn ($7.2M operating cash outflow YTD) consumes 51% of current cash in 9 months. Runway ~15 months at current rate. Phase 2 initiation is operational milestone but clinical-stage risk remains high. Material relative to $14M market cap but no new financing or partnership disclosed.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.